Amonafide in Combination With Cytarabine in Secondary AML
Public ClinicalTrials.gov record NCT00273884. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Open-Label Study of Amonafide L-Malate in Combination With Cytarabine in Subjects With Secondary Acute Myeloid Leukemia (AML)
Study identification
- NCT ID
- NCT00273884
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Xanthus Pharmaceuticals, Inc.
- Industry
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Interventions
- Amonafide L-Malate Drug
- Cytarabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2005
- Primary completion
- Not listed
- Completion
- Mar 31, 2009
- Last update posted
- Feb 18, 2007
2005 – 2009
United States locations
- U.S. sites
- 19
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham Comprehensive Cancer Center | Birmingham | Alabama | 35294-3300 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| UCLA Medical Center | Los Angeles | California | 90024 | — |
| Scripps Cancer Center | San Diego | California | 92121 | — |
| University of Colorado Health Sciences Center, Anschutz Cancer Center | Aurora | Colorado | 80010 | — |
| University of Florida Health Science Center | Gainesville | Florida | 32610-0277 | — |
| Northwestern University, Robert H. Lurie Comprehensive Cancer Center | Chicago | Illinois | 60611 | — |
| St. Francis Cancer Research Foundation (formerly Indiana Oncology Hematology Consultants and American Health Network of Indiana LLC, Oncology Division) | Indianapolis | Indiana | 46202 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| University of Massachusetts Memorial Medical Center | Worcester | Massachusetts | 01655 | — |
| University of Michigan | Ann Arbor | Michigan | 48109-0848 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 98198 7835 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 75246 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | — |
| MUSC - Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| West Virginia University Medical Center | Morgantown | West Virginia | 26506-9162 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00273884, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 18, 2007 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00273884 live on ClinicalTrials.gov.